Influx Healthtech shares list at 38% premium over IPO price on NSE SME
Influx Healthtech debuted strongly on the NSE SME platform, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96. The Rs 58.57 crore IPO, which closed on June 20, surpassed grey market expectations.
Tired of too many ads?
Remove Ads
IPO Overview
Tired of too many ads?
Remove Ads
Popular in Markets
1.
HAL shares in focus as delay-hit Tejas jets to reach IAF by March
Company background
Financials and Valuation
Healthcare-focused contract manufacturer Influx Healthtech made a strong debut on the NSE SME platform today, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96.The Rs 58.57 crore IPO had closed for subscription on June 20.Ahead of the listing, the grey market premium (GMP) for Influx Healthtech stood at around Rs 20, implying an expected listing price of Rs 116 — a potential gain of 20.83%. However, the stock surpassed grey market expectations with a significantly stronger opening.The IPO comprised a fresh issue of 50 lakh shares worth Rs 48 crore and an offer for sale (OFS) of 11 lakh shares worth Rs 10.56 crore, offering a total of 61,00,800 shares. The IPO price was fixed at Rs 96 per share.The anchor portion attracted Rs 16.67 crore, with shares allocated to institutional investors a day before the issue opened.Established in 2020, Influx Healthtech is a CDMO (Contract Development and Manufacturing Organization) providing end-to-end manufacturing and product development services for nutraceuticals, cosmetics, personal care, ayurvedic, veterinary, and homecare products.Operating out of three modern facilities in Thane, Maharashtra, the company boasts an extensive portfolio including gummies, capsules, powders, skincare products, herbal supplements, and veterinary feed formulations. It serves nutraceutical, cosmetic, and healthcare clients, handling everything from formulation and R&D to regulatory support and packaging.The company currently employs 163 people and continues to expand its product capabilities and client reach, focusing on innovation and scalability in fast-growing consumer health segments.Influx Healthtech posted a revenue of Rs 104.99 crore in FY25, up 5% year-on-year, while PAT rose 19% to Rs 13.37 crore. It maintains a robust ROE of 36.98%, EBITDA margin of 19.62%, and negligible debt.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
32 minutes ago
- Time of India
Samsung Galaxy Z Fold 7, Galaxy Z Flip 7 pre-reservation begin in India: Here's how you can pre-reserve the upcoming foldable smartphones
Samsung recently announced its Galaxy Unpacked 2025 event will take place on July 9 in Brooklyn, New York, at 10:00 AM ET (7:30 PM IST), where the tech giant is expected to unveil its next-generation Galaxy Z Fold 7 and Galaxy Z Flip 7 smartphones featuring a revolutionary AI-powered interface. The event will be livestreamed on Samsung's website and YouTube channel. The company has now started pre-reservation for its upcoming flagship foldable smartphone series in India. Samsung Galaxy Z Fold 7, Galaxy Z Flip 7 pre-reservation starts in India Samsung has now started pre-reservation for the upcoming Galaxy Z Fold 7 and Galaxy Z Flip 7 in India. The company has announced that customers can pre-reserve the upcoming foldable smartphones by paying a token amount of Rs 2,000. The company has also revealed that the customers who will pre-reserve the smartphone will get benefit worth Rs 5,999 on the purchase. Along with this, the customers will also be eligible for early delivery. Customers can pre-reserve the devices by visiting Samsung Exclusive Stores , and leading retail outlets across India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo What to expect at Samsung's Galaxy Unpacked July Expected product launches include the Galaxy Z Fold7, rumored to feature Samsung's largest foldable display yet at 8.2 inches, surpassing competitors. The Galaxy Z Flip7 will reportedly be powered by Samsung's newly introduced Exynos 2500 Deca-Core processor and come in jet black, blue shadow, and coral red variants. A more affordable Galaxy Z Flip 7 FE model is also anticipated. Beyond smartphones, Samsung is expected to expand its wearables portfolio with the Galaxy Watch 8 series, including standard, Classic, and Ultra 2025 models. The recently teased Galaxy Buds Core may also debut at the event. Additional announcements may include updates on Project Moohan, Samsung's collaboration with Google on extended reality headsets, and the company's rumored tri-fold smartphone development.
Business Standard
33 minutes ago
- Business Standard
SEPC successfully raises Rs 350 cr via rights issue
SEPC announced that it has achieved successful closure of rights issue of 74,35,19,173 partly paid-up equity shares aggregating to Rs 350 crore having issue price of Rs 10/- per equity share (including a share premium of Rs nil per share) (the issue price) on a rights basis to the eligible equity shareholders of our Company closed successfully on 23 June by Capital Market - Live News
Business Standard
33 minutes ago
- Business Standard
Lupin receives USFDA approval for generic Prucalopride tablets
Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for Prucalopride tablets. The tablets are a generic equivalent of Motegrity Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc., and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Lupin stated that the approved product is bioequivalent to Motegrity and will be manufactured at the companys facility in Goa, India. According to IQVIA MAT data for April 2025, Prucalopride Tablets (Reference Listed Drug: Motegrity) had estimated annual sales of approximately $184 million in the United States. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.07% to Rs 1,932.10 on the BSE.
